Abivax SA (ABVX PA) stock market data APIs
€71.971
-1.11(-1.5%)
as of September 15, 2025
Try our APIs with
free plan!
Abivax SA Financial Data Overview
Price chart is built with
Anychart
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
Prev. Close
71.971
Open
70.8609
High
72.0267
Low
68.5291
52 wk Range
4.51-78.7
Market Cap
5 495 M
Shares Outstanding
75 574 K
Revenue
6 023 K
EPS
-0.7631
Beta
0.127
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Abivax SA data using free add-ons & libraries
Get Abivax SA Fundamental Data
Abivax SA Fundamental data includes:
- Net Revenue: 6 023 K
- EBITDA: -185 652 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-09-08
- EPS/Forecast: -0.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Abivax SA News
New
2 Beaten-Down Stocks With Incredible Upside Potential
Key Points Viking Therapeutics' work in obesity treatment could lead to significant gains down the line. Recursion Pharmaceuticals could change the way drugs are developed. 10 stocks we like better t...
This Stock Is Up by 800% This Year -- but Is It a Buy?
Key Points Abivax's shares skyrocketed following positive clinical trial results for its lead candidate, obefazimod. This investigational medicine could prove more effective than existing drugs for u...
Rocket lays off staff; Abivax capitalizes on immune drug data
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving Rocket Pharm...
Abivax Announces Launch of Public Offering
Abivax Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clin...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
